Carrick NewsroomPress Releases

Elligo Health Research And Saama Technologies Announce Strategic Partnership To Advance Clinical Research Data Management

AUSTIN, TX & CAMPBELL, CA (February 28, 2018) – Elligo Health Research, which improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients, is partnering with Saama Technologies, Inc., a leading clinical data analytics company, to improve awareness of, access to, and participation in clinical trials for U.S. physicians and patients.

“We are excited to work with Saama to develop an innovative technology platform to transform the clinical research process overall, from standards-based data collection to eSubmissions to regulatory agencies,” said John Potthoff, Ph.D., Elligo CEO.

Through its Goes Direct™ model, Elligo engages physicians and their patients by first identifying patients using electronic health records and then providing their physicians with the infrastructure to conduct the research in their own offices at no cost to them. Saama’s award-winning Life Science Analytics Cloud, powered by its unique, AI-enabled Fluid Analytics Engine, includes the Cohort Builder and Trial Planning Optimizer solutions, which facilitate the identification of patient populations based on clinical trial eligibility requirements.

“Saama and Elligo have each pioneered innovative solutions that positively disrupt and improve the clinical trial landscape,” said Suresh Katta, founder and CEO of Saama. “Together, Saama and Elligo will set a new bar for physician and patient access to, and engagement with, clinical research that may improve patients’ health, enhance physicians’ understanding of disease management, and expand medical knowledge for treating some of the most prevalent and devastating human diseases.”

The partnership will help resolve the challenges sponsors face when they must assemble vast amounts of data from disparate sources.

“Saama’s groundbreaking analytics can deliver aggregated operational and clinical data to provide a multidimensional and real-time view of even multi-site trials,” Katta said. “By combining our life sciences solutions with Elligo’s unique approach and clinical research experience, we can improve data management to support accelerated research and development of meaningful therapeutics.”

“With Saama as a partner, Elligo will continue to improve access to standards-based eSource data directly from clinical research sites,” Potthoff added.

Meet with Saama and Elligo at the upcoming Bridging Clinical Research & Clinical Health Care Collaborative, April 4–5 in National Harbor, Md.

About Elligo

Elligo Health Research offers the only platform that brings clinical research to the clinic, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Elligo Goes Direct™ with an approach that uses electronic health records and other health data to identify real-world patients and physicians for participation in clinical studies. Elligo supports health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.

About Saama

Saama Technologies is the advanced data and analytics company delivering actionable business insights for life sciences and the Global 2000. Saama is singularly focused on driving fast, flexible, impactful business outcomes for clients through data and analytics. Saama’s unique “hybrid” approach integrates focused solutions and expertise across the life sciences domain, business consulting, data science, automated data management, and big data technologies. Saama integrates manual and disconnected initiatives into a well-aligned roadmap, facilitating the client’s journey from strategy through solution implementation.

About Carrick Capital Partners
Who We Are
A firm of enterprise software, SaaS, and technology enabled services investors and operating executives with substantial experience founding, scaling, and optimizing market leading businesses.
Our Approach
We work with management to identify and improve critical areas of their business - focusing on the priorities that align with our experiences and that will deliver the highest strategic impact in both the short-term and long-run.
Why We Are Different
We have a concentrated number of companies in our portfolio so that we can build substantial relationships with each management team and ensure our firm's commitment to each company's goals.
Latest News
Accolade Logo.jpg
Seattle, WA (July 1, 2020) - Accolade, Inc. ("Accolade"), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced the pricing of its initial public offering of 10,022,726 shares of its common stock at a price to the public of $22.00 per share. The shares are expected to begin trading on The Nasdaq Global Select Market under the ticker symbol "ACCD" on July 2, 2020, and the offering is expected to close on July 7, 2020, subject to customary closing conditions. In addition, Accolade has granted the underwriters a 30-day option to purchase up to 1,503,408 additional shares of common stock at the initial public offering price less the underwriting discount and commissions.
July 1, 2020
Mavenlink Logo.jpg
Irvine, CA (June 30, 2020) -- Mavenlink, the leading provider of cloud-based software for the modern services organization, today announced Steve DeSantis has joined its executive team as CFO to oversee essential business functions, guide organizational growth, and ensure Mavenlink continues to help professional services companies realize their full potential.
June 30, 2020
Carrick Logo TM.jpg
Technical Bootcamp To Continue Focus on Substantial Reskilling and Upskilling Labor Market Opportunity
June 30, 2020